Breath condensate levels of 8-isoprostane and leukotriene B4 after ozone inhalation are greater in sensitive versus nonsensitive subjects.
Ozone (O3) inhalation induces pulmonary function decrements and inflammation. The present study was designed to determine if a relationship exists between O3 induced pulmonary function changes and the presence of inflammatory markers as measured in exhaled breath condensates (EBCs) obtained from O3-sensitive and nonsensitive human subjects. Eight healthy adult volunteers (4 males/4 females, age 18 to 30 years) were studied, characterized as to their ozone sensitivity and placed into 2 groups (sensitive and nonsensitive) with each group having 2 males and 2 females. Subjects completed a 20-minute EBC collection and pulmonary function test (PFT) prior to a single 60-minute bout of cycle ergometer exercise (V(E) = 50-55 L/min) while breathing filtered air (FA) or 0.35 ppm O3. Subjective symptom scores (SSSs) were collected at 6, 20, 40, and 60 minutes during exposure. An immediate postexposure PFT was performed followed by an EBC collection. Subjective symptom scores, EBCs, and PFTs were collected at 1, 4 and 8 hours post exposure. EBCs were analyzed for prostaglandin E2 (PGE2), leukotriene B4 (LTB4), 8-isoprostane, and total nitric oxide (NO) metabolites (nitrate + nitrite content). Sensitive subjects, breathing O3, had significantly greater functional decrements in PFTs, increased SSSs, and increased rapid shallow breathing as well as elevated levels of 8-isoprostane and LTB4 in EBCs compared to those breathing FA. In addition, there were significant increases in nitrate + nitrite content in both sensitive and nonsensitive subjects breathing O3 compared to FA. These results indicate that sensitive subjects have elevated arachidonic acid metabolites in EBCs compared to nonsensitive subjects after O3 inhalation.
Alfaro
Mario F
MF
Department of Anatomy, Physiology and Cell Biology, School of Veterinary Medicine, University of California, Davis, California 95616, USA.
Walby
William F
WF
Adams
William C
WC
Schelegle
Edward S
ES
D000328:Adult; D000393:Air Pollutants / Q000009:adverse effects*; D015415:Biomarkers / Q000032:analysis; D001944:Breath Tests; D015237:Dinoprost / Q000031:analogs & derivatives* / Q000032:analysis; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D019570:Inhalation Exposure; D007975:Leukotriene B4 / Q000032:analysis*; D008171:Lung Diseases / Q000139:chemically induced* / Q000503:physiopathology; D008297:Male; D009566:Nitrates / Q000032:analysis; D009573:Nitrites / Q000032:analysis; D010126:Ozone / Q000009:adverse effects*; D015656:Respiratory Mechanics / Q000187:drug effects*; D013990:Tidal Volume / Q000187:drug effects; D013997:Time Factors; D014797:Vital Capacity / Q000187:drug effects
D000393:Air Pollutants; D015415:Biomarkers; D009566:Nitrates; D009573:Nitrites; D007975:Leukotriene B4; C075750:8-epi-prostaglandin F2alpha; D010126:Ozone; D015237:Dinoprost